Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
344 studies found for:    "Anaplastic astrocytoma"
Show Display Options
Rank Status Study
21 Recruiting Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Conditions: Recurrent Glioblastoma Multiforme;   Progressive Glioblastoma Multiforme;   Anaplastic Astrocytoma or Gliosarcoma
Intervention: Biological: M032 (NSC 733972)
22 Unknown  Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Intervention: Biological: transferrin-CRM107
23 Completed SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
Condition: Astrocytoma
Intervention: Drug: Temozolomide
24 Completed Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Conditions: Glioblastoma;   Astrocytoma
Interventions: Drug: Temozolomide;   Drug: Semustine
25 Recruiting TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Conditions: Brain Tumor;   Astrocytoma;   Astroglioma;   Glioblastoma;   Gliosarcoma
Interventions: Drug: TG02;   Drug: TMZ
26 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
27 Not yet recruiting Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Cabozantinib
28 Recruiting A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Intervention: Drug: Fingolimod
29 Completed Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: Temozolomide;   Radiation: Radiotherapy of the partial brain.
30 No longer available Expanded Access to ANG1005 for Individual Patients
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Breast Cancer With Recurrent Brain Metastases;   Leptomeningeal Carcinomatosis
Intervention: Drug: ANG1005
31 Terminated Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
Conditions: Glioblastoma Multiforme (WHO Grade IV);   Anaplastic Astrocytoma (WHO Grade III)
Interventions: Drug: 06Benzylguanine;   Genetic: MGMT P140K;   Device: Meltenyi CliniMacs
32 Terminated
Has Results
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
Conditions: Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma
Interventions: Drug: PD 0332991 (pre-surgery);   Drug: PD 0332991;   Procedure: Resection as clinical care
33 Completed IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: Surgery for placement;   Procedure: Radiation therapy;   Drug: Temozolomide with radiation therapy
34 Completed AMG 595 First-in-Human in Recurrent Gliomas
Conditions: Advanced Malignant Glioma;   Anaplastic Astrocytomas;   Glioblastoma Multiforme
Intervention: Drug: AMG 595
35 Not yet recruiting Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma
Conditions: Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Glioblastoma;   Anaplastic Astrocytoma
Interventions: Procedure: Laser Interstitial Thermal Therapy;   Drug: Lomustine;   Behavioral: Quality of Life Questionnaires;   Device: The NeuroBlate System
36 Not yet recruiting Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma
Conditions: High Grade Malignant Neoplasm;   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Interventions: Other: flourescein;   Other: intraoperative MRI
37 Completed PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Conditions: Gliosarcoma;   Glioblastoma;   Anaplastic Astrocytoma
Intervention: Drug: Temodar and SCH 66336
38 Completed Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Conditions: Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma
Intervention: Drug: Oral Topotecan and Temodar
39 Recruiting Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Conditions: Glioblastoma;   Anaplastic Astrocytoma;   Anaplastic Oligoastrocytoma;   Glioma;   Brain Neoplasm;   Brain Cancer;   Brain Tumor;   Brain Tumor, Recurrent;   Brain Neoplasm, Malignant
Interventions: Drug: Intra-arterial Cetuximab;   Drug: Intra-arterial Mannitol;   Radiation: Hypofractionated re-irradiation
40 Completed Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Procedure: conventional surgery;   Radiation: iodine I 131 monoclonal antibody TNT-1/B

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.